Canakinumab shows efficacy in Japanese AOSD patients in Phase 3 open-label study

This Phase III, open-label, single-arm active treatment study evaluated the efficacy, safety, tolerability, and pharmacokinetics/pharmacodynamics of canakinumab in Japanese participants with Adult-Onset Still's Disease (AOSD). The study enrolled 14 participants. The intervention was canakinumab administered subcutaneously at a dose of 4 mg/kg (up to a maximum of 300 mg) every 4 weeks for at least 48 weeks. The study consisted of a screening epoch (Day -28 to Day -1) and an open-label treatment epoch (Day 1 until either regulatory approval and commercial availability of canakinumab for adult Still's disease in Japan, or study termination). The primary outcome was the percentage of participants who achieved an adapted American College of Rheumatology (ACR) 30 response at Week 8. Interim analysis data collected at Weeks 28 and 48 supported the registration submission of canakinumab for the indication of Adult Still's Disease in Japan. The study was completed, with a primary completion date of 2025-04-16 and results posted on 2026-03-23. The study design was open-label and single-arm, which is a limitation as it lacks a comparator group for efficacy and safety assessments.

Imagine your body turning on itself, causing waves of high fever, painful rashes, and debilitating joint pain. That's the reality for people with Adult-Onset Still's Disease (AOSD), a rare inflammatory condition. A recent study looked at whether a monthly injection called canakinumab could help Japanese patients with this disease. The treatment was given just under the skin every four weeks for at least a year. The study was designed to see how well it worked, how safe it was, and how the body processed the drug. The main goal was to see how many people had a meaningful improvement in their symptoms—specifically, at least a 30% reduction in disease activity—by the eighth week of treatment. While the abstract doesn't give the exact percentage of people who improved, it does report that the data collected at 28 weeks and again at 48 weeks were strong enough to support submitting the drug for official approval to treat AOSD in Japan. This is a key step, as it means regulators saw enough evidence that the treatment could be beneficial. The study involved 14 participants and followed them closely during the treatment period.